[go: up one dir, main page]

MEP10608A - Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity - Google Patents

Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Info

Publication number
MEP10608A
MEP10608A MEP-106/08A MEP10608A MEP10608A ME P10608 A MEP10608 A ME P10608A ME P10608 A MEP10608 A ME P10608A ME P10608 A MEP10608 A ME P10608A
Authority
ME
Montenegro
Prior art keywords
dyslipidemia
obesity
prevention
treatment
pyrazole derivative
Prior art date
Application number
MEP-106/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Michele Arnone
Mohammed Bensaid
Jean-Marc Herbert
Hassan Massoud Heshmati
Philip Janiak
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34426973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP10608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0312553A external-priority patent/FR2861300B1/fr
Priority claimed from FR0314763A external-priority patent/FR2861301B1/fr
Priority claimed from FR0401193A external-priority patent/FR2861302A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP10608A publication Critical patent/MEP10608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-106/08A 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity MEP10608A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR0314763A FR2861301B1 (fr) 2003-10-24 2003-12-15 Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0401193A FR2861302A1 (fr) 2003-10-24 2004-02-05 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0403252A FR2861303A1 (fr) 2003-10-24 2004-03-26 Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
PCT/FR2004/002715 WO2005046689A2 (fr) 2003-10-24 2004-10-22 Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite

Publications (1)

Publication Number Publication Date
MEP10608A true MEP10608A (en) 2010-06-10

Family

ID=34426973

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-106/08A MEP10608A (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Country Status (18)

Country Link
US (2) US20070072907A1 (xx)
EP (1) EP1680117A2 (xx)
JP (1) JP2007509113A (xx)
KR (1) KR20060100443A (xx)
AR (3) AR047764A1 (xx)
AU (1) AU2004289078A1 (xx)
BR (1) BRPI0415538A (xx)
CA (1) CA2543582A1 (xx)
FR (1) FR2861303A1 (xx)
IL (1) IL175103A0 (xx)
MA (1) MA28105A1 (xx)
ME (1) MEP10608A (xx)
NZ (1) NZ547375A (xx)
RS (1) RS20060344A (xx)
RU (1) RU2357731C2 (xx)
SG (1) SG149078A1 (xx)
TW (1) TWI286935B (xx)
WO (1) WO2005046689A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ES2326857B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico.
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1745782A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome
ES2330993B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
WO2007009694A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Use of substituted pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome
RU2317809C1 (ru) * 2006-09-19 2008-02-27 Евгений Леонидович Калин Способ коррекции избыточной массы тела
EP1946779A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Combination of substituted pyrazolines and agent for treating dyslipidemia
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
ES2349838B1 (es) * 2009-05-04 2011-11-15 Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im Derivados de pirazol bivalentes como inhibidores de ingesta
RU2568896C2 (ru) * 2013-07-31 2015-11-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему
WO2018064654A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
AU777254B2 (en) * 1999-04-20 2004-10-07 Board Of Trustees Of Southern Illinois University, The Methods of treating clinical diseases with isoflavones
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
IL160081A0 (en) * 2001-09-21 2004-06-20 Solvay Pharm Bv Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US6864268B2 (en) * 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
PL375230A1 (en) * 2002-07-09 2005-11-28 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2004009015A2 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
ES2294330T3 (es) * 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20070099884A1 (en) * 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005039579A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
CA2557998A1 (en) * 2004-03-31 2005-10-13 Neurogen Corporation Combination therapy for weight management
US20050281868A1 (en) * 2004-06-21 2005-12-22 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy

Also Published As

Publication number Publication date
KR20060100443A (ko) 2006-09-20
TW200526216A (en) 2005-08-16
EP1680117A2 (fr) 2006-07-19
NZ547375A (en) 2009-10-30
WO2005046689A2 (fr) 2005-05-26
AU2004289078A1 (en) 2005-05-26
AR047764A1 (es) 2006-02-22
AR063551A2 (es) 2009-01-28
TWI286935B (en) 2007-09-21
IL175103A0 (en) 2008-04-13
US20070072907A1 (en) 2007-03-29
RS20060344A (sr) 2008-08-07
RU2006117790A (ru) 2007-12-10
BRPI0415538A (pt) 2006-12-26
AR063550A2 (es) 2009-01-28
SG149078A1 (en) 2009-01-29
FR2861303A1 (fr) 2005-04-29
CA2543582A1 (fr) 2005-05-26
JP2007509113A (ja) 2007-04-12
WO2005046689A3 (fr) 2005-10-13
MA28105A1 (fr) 2006-08-01
US20090215755A1 (en) 2009-08-27
RU2357731C2 (ru) 2009-06-10

Similar Documents

Publication Publication Date Title
MEP10608A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
EE04836B1 (et) N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
YU53901A (sh) Derivati pirazolokarboksilne kiseline, njihova priprema, farmaceutske kompozicije sa sadržajem istih
AR027548A1 (es) Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
WO2007123949A3 (en) Cannabinoid receptor modulators
ATE397601T1 (de) Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
MX2008013040A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1.
IL191936A0 (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
WO2007017126A3 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
NO20052197D0 (no) Fremgangsmate for fremstilling av pyrazol
HRP20090393T1 (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento
ATE500228T1 (de) 4,5-dihydro-(1h)-pyrazol-derivate als cannabinoid-cb1-rezeptormodulatoren
TW200640458A (en) Use of a pyrazole derivative for preparing medicinal products that are of use in the prevention and treatment of kidney diseases
TH74718A (th) การใช้อนุพันธ์ของไพราโซลสำหรับการเตรียมผลิตภัณฑ์ทางยาซึ่งใช้ได้ดีในการป้องกันและการบำบัดหลอมลมอักเสบแบบเรื้อรังและโรคปอดอุดตันแบบเรื้อรัง
EA201070019A1 (ru) 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
TH81014A (th) การใช้อนุพันธ์ไพราโซลสำหรับการเตรียมผลิตภัณฑ์ยาซึ่งใช้ในการป้องกัน และการรักษาโรคไต
UA84594C2 (xx) 1,3,5-тризаміщені похідні 4,5-дигідро-1h-піразолу з антагоністичною активністю щодо cb1[1,3,5-тризамещенные производные 4,5-дигидро-1н-пиразола в качестве антагонистов св1
UY28576A1 (es) Utilización de un derivado de pirazol para la preparación de medicamentos utiles para la prevención y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
TH112716A (th) สารประกอบชนิดมัลติ-ไซคลิค